Genentech, Inc., et al. v. Sandoz, Inc., et al.
1:19-cv-00078 | Delaware District Court
Interested in this case?
Request a Demo Track this case, and find millions of cases like it, let us show you how.Upcoming Events | ||
---|---|---|
18 Months
| Source Add |
Filing Date | # | Docket Text |
---|---|---|
2/3/2023 | Remark: The bench trial exhibits (see D.I. 362 Exhibit List) have been destroyed per the authority at D.I. 439 . (nms) (Entered: 02/03/2023) | |
2/3/2023 | 439 | Joint Letter to The Clerk of Court, regarding the discarding of trial exhibits (D.I. 438 ). (Clark, Cameron) Modified on 2/3/2023 (nms). (Entered: 02/03/2023) |
1/30/2023 | 438 | Letter to Counsel, from the Clerk of Court, regarding return of trial exhibits -(see D.I. 362 Exhibit List). (nms) (Entered: 01/30/2023) |
1/30/2023 | 437 | MANDATE of USCA as to 397 Notice of Appeal (Federal Circuit), filed by Genentech, Inc., InterMune, Inc.. USCA Decision: Affirmed. (Attachments: # 1 Opinion, # 2 Judgment)(nms) (Entered: 01/30/2023) |
10/6/2022 | 436 | ORAL ORDER: The redactions at D.I. 389 , 390 , 391 , and 393 as supported by the declarations at D.I. 403 and D.I. 404 are APPROVED. Ordered by Judge Richard G. Andrews on 10/6/2022. (nms) (Entered: 10/06/2022) |
6/16/2022 | 435 | MANDATE of USCA as to 433 Notice of Cross Appeal, filed by Lek Pharmaceuticals D.D., Sandoz Inc.. USCA Decision: The motion is granted. Appeal No. 2022-1714 is dismissed. The revised official caption for the remaining appeal, Appeal No. 2022-1595, is reflected above. (2) Each side shall bear its own costs in Appeal No. 2022-1714. (3) The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal No. 2022 1595. (4) Genentech, Inc. and InterMune, Inc.s reply brief in Appeal No. 2022-1595 is due no later than July 5, 2022. (nms) (Entered: 06/16/2022) |
4/22/2022 | 434 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 433 Notice of Cross Appeal, filed by Lek Pharmaceuticals D.D., Sandoz Inc.. USCA Case Number 2022-1714. (nms) (Entered: 04/22/2022) |
4/21/2022 | Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re 433 Notice of Cross Appeal. (nmg) (Entered: 04/21/2022) | |
4/21/2022 | Notification regarding 433 Notice of Cross Appeal sent to Reporter Triozzi. (nmg) (Entered: 04/21/2022) | |
4/21/2022 | APPEAL - Credit Card Payment of $505.00 received re 433 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. ( Filing fee $505, receipt number ADEDC-3856953.) (Brauerman, Stephen) (Entered: 04/21/2022) | |
4/21/2022 | 433 | NOTICE OF CROSS APPEAL to the Federal Circuit of 396 Judgment . Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) (Entered: 04/21/2022) |
4/20/2022 | 432 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s): 7,767,225 B2; 7,988,994 B2; 8,383,150 B2; 8,753,679 B2; 7,696,236 B2; 7,767,700 B2; 8,420,674 B2; 7,566,729 B1; 7,635,707 B1; 8,592,462 B2; 8,609,701 B2; 7,816,383 B1; 7,910,610 B1; 8,013,002 B2; 8,084,475 B2; 8,318,780 B2; 8,648,098 B2; 8,754,109 B2; 8,778,947 B2. (Attachments: # 1 Final Judgment)(nms) (Entered: 04/20/2022) |
4/19/2022 | 431 | REDACTED VERSION of 415 Declaration by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibits 1-46)(Clark, Cameron) (Entered: 04/19/2022) |
4/19/2022 | 430 | REDACTED VERSION of 413 Declaration by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibits A-C)(Clark, Cameron) (Entered: 04/19/2022) |
4/19/2022 | 429 | REDACTED VERSION of 412 Reply Brief by Genentech, Inc., InterMune, Inc.. (Clark, Cameron) (Entered: 04/19/2022) |
4/19/2022 | 428 | REDACTED VERSION of 414 Declaration by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibit A)(Clark, Cameron) (Entered: 04/19/2022) |
4/19/2022 | 427 | ORDER UNSEALING DOCUMENTS: The Muzumdar Declaration and its eight exhibits (D.I. 410 ) are UNSEALED. Signed by Judge Richard G. Andrews on 4/19/2022. (nms) (Entered: 04/19/2022) |
4/19/2022 | CASE CLOSED per entry of D.I. 396 in Lead Civil Action 19-78-RGA. Associated Cases: 1:19-cv-00078-RGA, 1:19-cv-00202-RGA, 1:19-cv-00203-RGA(nms) (Entered: 04/19/2022) | |
4/18/2022 | Minute Entry for proceedings held before Judge Richard G. Andrews - Hearing on the Emergency Motion for Temporary Restraining Order and Injunction Pending Appeal held on 4/18/2022. Counsel for Plaintiffs: K. Jacobs. Counsel for Defendants: R. Golden. (Court Reporter Heather Triozzi.) (lak) (Entered: 04/18/2022) | |
4/18/2022 | 426 | REDACTED VERSION of 410 Declaration of Nimish Muzumdari, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8)(Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 425 | DECLARATION of Nimish Muzumdar in Support of Defendants' Redactions (D.I. 407 , 405 , 408 , and 410 ), by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 424 | ORDER: After consideration of the briefing and oral argument, and for the reasons stated in open court, IT IS HEREBY ORDERED this 18th day of April, 2022, that the Emergency Motion for Temporary Restraining Order and Injunction Pending Appeal (D.I. 388 ) is DENIED. Signed by Judge Richard G. Andrews on 4/18/2022. (nms) (Entered: 04/18/2022) |
4/18/2022 | 423 | DECLARATION of Kathleen McGuinness in support of Defendants' Redactions (D.I. 407 , 405 , and 406 ), by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 422 | DECLARATION of Jocelyn Binet in Support of Defendants' Redactions (D.I. 409 , and 407 ), by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 421 | REDACTED VERSION of 409 Declaration of Mauricio Ede-Filho, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 420 | REDACTED VERSION of 408 Declaration of Thomas Bongiovanni, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 419 | REDACTED VERSION of 407 Declaration of David Blackburn, Ph.D., by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21)(Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 418 | REDACTED VERSION of 406 Declaration of Lee Morrow, M.D., by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Brauerman, Stephen) Modified on 4/18/2022 (nms). (Entered: 04/18/2022) |
4/18/2022 | 417 | REDACTED VERSION of 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Brauerman, Stephen) (Entered: 04/18/2022) |
4/14/2022 | 416 | TRANSCRIPT REQUEST by Genentech, Inc., InterMune, Inc. TRANSCRIPT NOT NEEDED (Clark, Cameron) (Entered: 04/14/2022) |
4/12/2022 | 415 | [SEALED] DECLARATION of Christopher A. Vellturo, Ph.D. re 412 Reply Brief, by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibits 1-46)(Jacobs, Karen) Modified on 4/13/2022 (nms). (Entered: 04/12/2022) |
4/12/2022 | 414 | [SEALED] DECLARATION of Steven D. Nathan, M.D. re 412 Reply Brief, by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibit A)(Jacobs, Karen) Modified on 4/13/2022 (nms). (Entered: 04/12/2022) |
4/12/2022 | 413 | [SEALED] DECLARATION of Kira A. Davis re 412 Reply Brief, by Genentech, Inc., InterMune, Inc.. (Attachments: # 1 Exhibits A-C)(Jacobs, Karen) Modified on 4/13/2022 (nms). (Entered: 04/12/2022) |
4/12/2022 | 412 | [SEALED] REPLY BRIEF re 388 EMERGENCY Motion for Temporary Restraining Order and Injunction Pending Appeal filed by Genentech, Inc., InterMune, Inc.. (Jacobs, Karen) (Entered: 04/12/2022) |
4/12/2022 | 411 | ORAL ORDER: A hearing on the Emergency Motion for Temporary Restraining Order and Injunction Pending Appeal (D.I. 388 ) is now set for 4/18/2022, at 3:00 PM in Courtroom 6A. Each side will be limited to 20 minutes. Ordered by Judge Richard G. Andrews on 4/12/2022. (nms) (Entered: 04/12/2022) |
4/8/2022 | 410 | DECLARATION of Nimish Muzumdar re 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Certificate of Service)(Brauerman, Stephen) Modified on 4/11/2022 (nms). Modified on 4/19/2022 (nms). (Entered: 04/08/2022) |
4/8/2022 | 409 | [SEALED] DECLARATION of Mauricio Ede-Filho re 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Certificate of Service)(Brauerman, Stephen) Modified on 4/11/2022 (nms). (Entered: 04/08/2022) |
4/8/2022 | 408 | [SEALED] DECLARATION of Thomas Bongiovanni re 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Certificate of Service)(Brauerman, Stephen) Modified on 4/11/2022 (nms). (Entered: 04/08/2022) |
4/8/2022 | 407 | [SEALED] DECLARATION of David Blackburn, Ph.D. re 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Certificate of Service)(Brauerman, Stephen) Modified on 4/11/2022 (nms). (Entered: 04/08/2022) |
4/8/2022 | 406 | [SEALED] DECLARATION of Lee Morrow, M.D. re 405 Answering Brief in Opposition, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Certificate of Service)(Brauerman, Stephen) Modified on 4/11/2022 (nms). (Entered: 04/08/2022) |